We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

Download Mobile App




WBC Count Could Predict Severity of COVID-19 Symptoms

By LabMedica International staff writers
Posted on 03 Feb 2025

The global health crisis caused by the SARS-CoV-2 virus continues to impact millions of people worldwide, with many experiencing persistent symptoms months after the initial diagnosis. More...

Cognitive impairment and fatigue are among the most common lingering effects, with a staggering 70% of patients suffering from cognitive impairment. Older adults, particularly women, are disproportionately affected. Despite significant advances in understanding COVID-19 since its emergence in 2020, several aspects of its impact on the human body remain unclear. While COVID-19 is primarily a respiratory disease, research has revealed widespread effects on multiple organ systems. Previous studies have identified an exaggerated immune response to COVID-19 infection. Now, a new study has shed light on a potential indicator of the most likely patients to experience severe symptoms of COVID-19 infection: leukocyte (white blood cell) count.

This study drew on data from the Women's Health Initiative, a comprehensive research project funded by the National Institutes of Health (NIH, Bethesda, MD, USA). Researchers sought to investigate pre-existing risk factors that might make older adults, particularly postmenopausal women, more susceptible to prolonged and severe symptoms. They examined the relationship between leukocyte count, a readily available clinical marker of systemic inflammation, and COVID disease outcomes. Their findings, published in the journal Menopause, suggest that leukocyte count is a reliable predictor of COVID symptom severity in postmenopausal women. This research contributes to the growing evidence that low-grade inflammation is not only an outcome of severe COVID-19 symptoms but also a potential precursor to the acute infection. Further investigation is needed, but the initial findings hold promise, as leukocyte count represents a relatively inexpensive and easily accessible clinical marker.

“As the authors highlight, post-acute sequelae of severe acute respiratory coronavirus 2 infection significantly affects quality of life, often leading to severe disability,” said Dr. Monica Christmas, associate medical director for The Menopause Society. “This effect is particularly pronounced in women, who already experience higher rates of cognitive impairment after menopause. By understanding underlying factors, we can better address these challenges and work to mitigate the cascade of symptoms that follow.”


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
New
Alzheimer's Disease Biomarker Assay
Elecsys Phospho-Tau (217P) Plasma
Gold Member
Neonatal Heel Incision Device
Tenderfoot
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: Guardant Health has introduced new applications for Guardant360 Liquid, expanding the test’s capabilities for treatment selection in breast and lung cancers. (Photo courtesy of Guardant Health)

Liquid Biopsy Expands Insights Into Treatment Response and Tumor Alterations

Treatment selection in advanced breast and lung cancers can be challenging when traditional biomarkers are absent and genomic findings alone do not fully clarify which therapies may be effective.... Read more

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: VITEK PRO combines microbial identification and antimicrobial susceptibility testing on a single platform to support routine microbiology workflows and antibiotic selection. (Photo courtesy of bioMérieux)

Automated Microbial Identification and Susceptibility System Gains FDA Clearance

Antimicrobial resistance (AMR) is a leading global public health threat, causing an estimated 1.27 million deaths annually. The growing challenge of diagnosing and treating resistant infections highlights... Read more

Pathology

view channel
AI: Artificial intelligence; CNN: Convolutional neural networks; ResNet: Residual neural network. (Xing-hua Gao from The First Hospital of China Medical University, China Image Source Link: https://www.ovid.com/jnls/cmj/fulltext/10.1097/cm9.0000000000004154~deep-learning-based-computational-pathology-technologies)

Review Highlights Progress and Validation Needs for AI in Digital Pathology

Pathology remains the gold standard for disease diagnosis, but clinical laboratories face growing demands for faster, more reproducible diagnostic and prognostic workflows. Digital pathology based on whole-slide... Read more

Industry

view channel
Image: The collaboration aims to expand access to the technology through a regulated clinical diagnostics pathway in Japan.

Partnership Aims to Bring Blood-Based Alzheimer’s Testing to Japan

Alzheimer’s disease remains a growing diagnostic challenge as populations age and cognitive impairment becomes more common. In Japan, government-supported estimates project that approximately 4.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.